Skip to main content
Industry News
First-line lorlatinib beneficial in ALK-positive NSCLC

Researchers found that people with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who received first-line lorlatinib treatment had significantly improved progression-free survival, as well as significantly higher objective and cranial response rates, compared with those who were given first-line crizotinib. The findings, presented at the virtual congress of the European Society of Medical Oncology, also correlated lorlatinib with better quality of life as reported by patients.

Full Story: